April 13, 2007 -- SinoBiomed announced that its subsidiary Shanghai Wanxing received approval in China for its lyophilized recombinant human acidic fibroblast growth factor for external use (rhaFGF). The drug is indicated for ulceration, including deep burns and chronic ulcers caused by wounds, diabetes, vascular diseases and bed sores. Before distributing the drug, Shanghai Wanxing must also win GMP Certification. SinoBiomed, which is based in Shanghai, was formed in early March 2007, when CDoor Corporation took over Wanxing and its subsidiaries by issuing 1.75 million shares to Wanxing shareholders. CDoor changed its name to SinoBiomed. More details...
